".....A second product the company is working on is Perifosine
which is an oral anti-cancer drug. For the science folks out there, it inhibits Akt activation in the phosphoinositide pathway. For the common person that basically means that the drug attempts to stop the growth of the cancer and might even shrink it. Keryx has the drug on license from another company. In September 2002, the company entered a commercial license agreement with Zentaris AG, a wholly-owned subsidiary of AEterna Zentaris Inc. This agreement granted exclusive rights to Perifosine in the U.S., Canada, and Mexico. At the current time 2,000 patients in the US and Europe have been involved with the trials of this new drug. So far the safety tests have done very well. Side effects have been much less severe as compared to other medicines that are currently used to treat this illness.
If both products were to be accepted by the FDA then the valuation of the stock price would be much higher than it is today. Trying to come up with a more specific number is just not possible at this point in time. Often times companies like this get bought out pretty quickly. If not then the company will often time have secondary offerings to raise funds to cover the costs of ramping up. So trying to come up with a good number is almost impossible. Currently the stock trades around $5 and seems to be held in place by the option dealers who make money by using calls and puts to generate cash. As the stock moves closer to its final date with the FDA approval process though, one will find it break those chains and move up in value rather quickly."